Immatics N.V

XNAS:IMTX  
10.04
0.00 (0.00%)
5:54:33 PM EDT: $10.04 0.00 (0.00%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.35B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$11.15 Million
Adjusted EPS-$0.47
See more estimates
10-Day MA$10.23
50-Day MA$10.10
200-Day MA$6.62
See more pivots

Immatics N.V Stock, XNAS:IMTX

Paul-Ehrlich-Strasse 19, Tuebingen, Baden Wuerttemberg 72076
Germany
Phone: +49.7071.5397.0
Number of Employees: 343
http://www.immatics.com

Description

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics. The company was founded on March 10, 2020, and is headquartered in Tuebingen, Germany.